RECORD | Already taken place Fr, 17.4.2026
Peptide 360 Episode 3 webinar on LC-MS bioanalysis of GLP-1 peptides in plasma for PK studies and development decisions.Go to the webinar
Quantifying GLP-1 Peptides in Plasma: Bioanalytical Workflows for PK and Development
Agilent Technologies: Peptide 360: Mastering the Invisible from Sequence to Confidence
A five-part webinar series unlocking advanced insights across the Peptide therapeutics workflows
Peptide therapeutics are reshaping modern medicine, with GLP-1 receptor agonists driving rapid advances in metabolic disease treatment. As peptide and GLP-1 programs scale, scientists face increasing pressure to generate data that is accurate, defensible, and decision-ready across development stages.
Peptide 360 is designed to guide scientists through this complexity, following the peptide workflow from sequence insight to confident development decisions.
Who Should Attend?
This series is designed for scientists and technical leaders working in peptide and GLP-1 discovery and development, analytical development, characterization, Bioanalysis, DMPK, translational research, CMC, QA/QC, and regulatory-facing analytical roles
How the Series Works?
- Register once for the full series
- Pre-submit questions for live expert responses
- Access recordings anytime after each session
- Certificate of attendance provided
Episode 3: Quantifying GLP-1 Peptides in Plasma: Bioanalytical Workflows for PK and Development
As GLP-1 peptide therapeutics advance through development, understanding how these molecules behave in biological systems becomes critical. Accurate measurement of GLP-1 analogs in plasma is essential for generating reliable pharmacokinetic and toxicokinetic data. This session explores bioanalytical workflows that combine automated sample cleanup with sensitive LC/MS-based quantitation to overcome the limitations of traditional antibody-based assays.
Attendees will learn how automation and mass spectrometry enable faster method development, improved specificity, and robust quantitation in complex biological matrices. The session highlights how bioanalysis strengthens development decisions by linking molecular design to in-vivo performance.
Presenter: Xi Qiu, Ph.D. (LC-MS Application Scientist, Agilent Technologies, Inc.)
Presenter: Ashish Pargaonkar, Ph.D. (Biopharma Applications Specialist, Agilent Technologies, Inc.)
